Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats
Autore:
Dorrance, AM; Osborn, HL; Grekin, R; Webb, RC;
Indirizzi:
Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA Med Coll Georgia Augusta GA USA 30912 Dept Physiol, Augusta, GA 30912 USA Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 ept Physiol, Ann Arbor, MI 48109 USA Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 nternal Med, Ann Arbor, MI 48109 USA
Titolo Testata:
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
fascicolo: 3, volume: 281, anno: 2001,
pagine: R944 - R950
SICI:
0363-6119(200109)281:3<R944:SRCISA>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL GROWTH-FACTOR; HYPERTENSIVE RATS; ARTERY OCCLUSION; CELLS; ALDOSTERONE;
Keywords:
cerebral ischemia; hypertension; mineralocorticoid;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Dorrance, AM Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA Med Coll Georgia 1120 15th St Augusta GA USA 30912 30912 USA
Citazione:
A.M. Dorrance et al., "Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats", AM J P-REG, 281(3), 2001, pp. R944-R950

Abstract

Remodeling of the cerebral vasculature contributes to the pathogenesis of cerebral ischemia. Remodeling is caused by increased smooth muscle proliferation and may be due to an increase in the responsiveness of vascular cellsto epidermal growth factor (EGF). Aldosterone is a risk factor for stroke,and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR). We hypothesized that mRNA for the EGF-stimulated pathway would be elevated in the vasculature of stroke-prone spontaneously hypertensive rats (SHRSP) and that this and experimental ischemic cerebral infract size would be reduced by aldosterone inhibition with spironolactone. We found that spironolactone treatment reduced the size of cerebral infarcts after middle cerebral artery occlusion in SHRSP (51.69 +/-3.60 vs. 22.00 +/-6.69% of hemisphere-infarcted SHRSP vs. SHRSP + spironolactoneP<0.05). Expression of EGF and EGFR mRNA was higher in cerebral vessels and aorta from adult SHRSP compared with Wistar-Kyoto rats. Only the expression of EGFR mRNA was elevated in the young SHRSP. Spironolactone reduced theEGFR mRNA expression in the aorta (1.09<plus/minus>0.25 vs. 0.56 +/-0.11 phosphorimage units SHRSP vs. SHRSP + spironolactone P<0.05) but had no effect on EGF mRNA. In vitro incubation of aorta with aldosterone <plus/minus> spironolactone produced similar results, suggesting a direct effect of aldosterone. Thus spironolactone may reduce the size of cerebral infarcts via areduction in the expression of the EGFR mRNA, leading to reduced remodeling.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/05/18 alle ore 13:05:59